Clinical trial registry record

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 8, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05439629
Last registry update
December 8, 2025
Status
Completed
Phase
Phase 3
Sponsor
Bio-Thera Solutions
Enrollment
488
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
488
Population
ALL · 50 Years to 85 Years
Duration
2022-07-07 to 2025-04-22
Intervention
BAT5906 injection; Lucentis
Comparator
Control group：Lucentis®
Outcomes measured
The change in the BCVA value — Week 52; The change in the BCVA value — at weeks 12, 24, 36, and 48; BCVA increased the proportion of subjects with >10, >15, ≥30 words — in the 24th and 52nd weeks; BCVA reduced the proportion of subjects < 10, < 15 words — at weeks 24 and 52; Changes in the thickness of the macular fovea (CRT). — at weeks 12, 24, 36, 48, and 52; Vital signs — Weeks 1 to 52; physical examination — Weeks 1 to 52; Laboratory tests — Weeks 1 to 52; electrocardiogram（ ECG ） — Weeks 1 to 52; Antibiotic antibodies (ADA) — Weeks 1 to 52; Adverse events（AE） — Weeks 1 to 52; Adverse events of particular concern (possible adverse reactions to the eye) — Weeks 1 to 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON